ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 948

Antibody-Based Prediction Rules for Connective Tissue Disease: Analysis of 12,555 Patients with Antinuclear Antibody Testing

Ryo Rokutanda1, Mitsumasa Kishimoto1, Yasuharu Tokuda2, Ken-ichi Yamaguchi1, Hisanori Shimizu1, Yasuhiro Suyama1, Yuri Ohara1, Yoichiro Haji1, Chisun Min1, Akira Takeda1, Yukio Matsui3 and Masato Okada1, 1Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 2Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan, 3Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Antibodies, Antinuclear antibodies (ANA), diagnosis, mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Antinuclear antibody (ANA) is widely used as a screening test for connective tissue diseases (CTDs). The sensitivity of this test is high in 3 CTDs–systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and mixed connective tissue disease (MCTD). ANA-associated specific autoantibodies are also identifiable in 3 additional CTDs including polymyositis and dermatomyositis (PM/DM), as well as primary Sjögren syndrome (SS).  However, appropriate cutoff points for ANA titers or in combination with other CTD-specific antibodies remains unclear.

Methods: We reviewed records for all patients (n=12,555) with ANA immunofluorescence assay testing from January 2003 to June 2012. Among 3302 patients with positive ANA (³a40), 94 were excluded due to lack of information about ANA titers. Data collection also included specific CTD diagnoses, ANA titers, and results of specific antibody tests for DNA, Sm, U1RNP, Ro, La, centromere, Scl-70, and RNA polymerase III. We calculated sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values for diagnosing each CTD at different ANA cutoffs. We then performed classification and regression tree (CART) analysis to develop prediction rules for each CTD. Potential predictors included ANA titers, ANA staining patterns, and specific antibody test results.

Results: Of 12,461 patients with ANA testing, 665 patients (5.3%) were diagnosed as having at least one of the 6 CTDs of interest. Area under the ROC curves of ANA testing were 0.943, 0.977, 0.926, 0.840, and 0.740 for SLE, MCTD, SSc, SS, and PM/DM, respectively. The sensitivities of ANA (³a40) for SLE, SSC, MCTD, SS, PM/DM were 98.6%, 95.9%, 100%, 83.0%, and 69.6%, while PPV was 6.7%, 5.1%, 0.7%, 6.3, and 1.7%, respectively. Prediction rules developed by CART were as follows: (1) ANA (³a40) with anti-DNA antibody (PPV: 70.3% for SLE), (2) ANA (³a40) with anti-U1RNP antibody (PPV: 26.8% for MCTD), (3) ANA (³a320) with anti-centromere antibody (PPV: 44.7% for SSc), and (4) ANA (³a320) and anti-Ro without anti-DNA (PPV: 49% for SS).

Conclusion: ANA testing demonstrates substantial sensitivity, but has low PPV for CTDs. Nonetheless, in combination with other antibody testing, our prediction rules reveal a high specificity and PPV for diagnosing CTDs.


Disclosure:

R. Rokutanda,
None;

M. Kishimoto,
None;

Y. Tokuda,
None;

K. I. Yamaguchi,
None;

H. Shimizu,
None;

Y. Suyama,
None;

Y. Ohara,
None;

Y. Haji,
None;

C. Min,
None;

A. Takeda,
None;

Y. Matsui,
None;

M. Okada,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibody-based-prediction-rules-for-connective-tissue-disease-analysis-of-12555-patients-with-antinuclear-antibody-testing/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology